Treatment with systemic immunostimulatory agents (including but not limited to interferons or interleukin-) within  weeks or five half-lives of the drug, whichever is shorter, prior to randomization
Treatment with systemic immunosuppressive medications (including but not limited to interferons, IL-) within  days or  half-lives of the drug, whichever is longer, prior to randomization.
Treatment with systemic immunostimulatory agents (including but not limited to interferons or Interlukin- [IL-]) within  weeks or five half-lives of the drug (whichever is shorter) prior to randomization
Treatment with systemic immunostimulatory agents (including but not limited to interferons or IL-) within  weeks or five half-lives of the drug, whichever is shorter, from cycle  day .
Treatment with systemic immunostimulatory agents (including but not limited to interferons or interleukin [IL]-) within  weeks or five half-lives of the drug (whichever is longer) prior to randomisation
Treatment with systemic immunostimulatory agents (including but not limited to interferons or interleukin-) within  weeks or five half-lives of the drug, whichever is shorter, prior to enrollment
Interferons:  weeks
Treatment with systemic immunostimulatory agents (including but not limited to interferons or interleukin [IL]-) within  weeks or five half-lives of the drug, whichever is shorter
Treatment with systemic immunostimulatory agents (including but not limited to interferons or interleukin-) within  weeks or five half-lives of the drug, whichever is shorter, prior to enrollment
Treatment with systemic immunosuppressive medications (including but not limited to interferons, IL-) within  weeks or  half-lives of the drug, whichever is longer, prior to randomization
Patients treated with systemic immunostimulatory agents (such as interferons, IL ) within  weeks of the start of the treatment or  half-lives of the drug, whichever is shorter
Treatment with systemic immunostimulatory agents (including but not limited to interferons or interleukin  [IL-]) within  weeks or five drug elimination half-lives prior to Day  of Cycle , whichever is longer
Treatment with systemic immunostimulatory agents (including but not limited to interferons or IL-) within  weeks or five half-lives of the drug (whichever is shorter) prior to randomization